WO1997035881A3 - Receptor and transporter antagonists - Google Patents

Receptor and transporter antagonists Download PDF

Info

Publication number
WO1997035881A3
WO1997035881A3 PCT/CA1997/000203 CA9700203W WO9735881A3 WO 1997035881 A3 WO1997035881 A3 WO 1997035881A3 CA 9700203 W CA9700203 W CA 9700203W WO 9735881 A3 WO9735881 A3 WO 9735881A3
Authority
WO
WIPO (PCT)
Prior art keywords
integral membrane
antagonists
receptor
membrane protein
transporter antagonists
Prior art date
Application number
PCT/CA1997/000203
Other languages
French (fr)
Other versions
WO1997035881A2 (en
Inventor
Godron Y K Ng
Philip Seeman
Susan R George
Brian F O'dowd
Original Assignee
Ng Gordon Y K
Philip Seeman
Susan R George
Brian F O'dowd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ng Gordon Y K, Philip Seeman, Susan R George, Brian F O'dowd filed Critical Ng Gordon Y K
Priority to EP97908101A priority Critical patent/EP0906339A2/en
Priority to AU20204/97A priority patent/AU2020497A/en
Publication of WO1997035881A2 publication Critical patent/WO1997035881A2/en
Publication of WO1997035881A3 publication Critical patent/WO1997035881A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Specific antagonists for prokaryotic or eukaryotic integral membrane proteins are provided. The antagonists are peptides having the amino acid sequence of a transmembrane domain of the integral membrane proteins or of a portion of analogue thereof. Methods are provided for preventing or treating disorders characterised by disordered function of an integral membrane protein by administration of a specific peptide antagonist of the integral membrane protein.
PCT/CA1997/000203 1996-03-27 1997-03-26 Receptor and transporter antagonists WO1997035881A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97908101A EP0906339A2 (en) 1996-03-27 1997-03-26 Receptor and transporter antagonists
AU20204/97A AU2020497A (en) 1996-03-27 1997-03-26 Receptor and transporter antagonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1430696P 1996-03-27 1996-03-27
US60/014,306 1996-03-27
US67011996A 1996-06-25 1996-06-25
US08/670,119 1996-06-25
US2424096P 1996-08-20 1996-08-20
US60/024,240 1996-08-20

Publications (2)

Publication Number Publication Date
WO1997035881A2 WO1997035881A2 (en) 1997-10-02
WO1997035881A3 true WO1997035881A3 (en) 1998-07-16

Family

ID=27360064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000203 WO1997035881A2 (en) 1996-03-27 1997-03-26 Receptor and transporter antagonists

Country Status (4)

Country Link
EP (1) EP0906339A2 (en)
AU (1) AU2020497A (en)
CA (1) CA2250567A1 (en)
WO (1) WO1997035881A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
WO1998000538A2 (en) * 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
ES2299242T3 (en) * 1998-02-27 2008-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services ANTAGONISTS OF PROTEIN G.
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
WO2001016182A2 (en) * 1999-08-27 2001-03-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
US7304127B2 (en) 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
US7517849B1 (en) * 1999-11-18 2009-04-14 The United States Of America As Represented By The Secretary Of Health And Human Services Inhibition of ABC transporters by transmembrane domain analogs
EP1217066A1 (en) * 2000-12-21 2002-06-26 Universiteit Gent Modulation of ATP-binding cassette transporter activity
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7067113B2 (en) 2002-01-18 2006-06-27 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
ES2228268B1 (en) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. COMBINATION OF ACTIVE SUBSTANCES CONTAINING AT LEAST ONE COMPOUND WITH AFFINITY FOR THE NEUROPEPTIDE RECEIVER AND (NPY) AND AT LEAST ONE COMPOUND WITH AFFINITY FOR THE RECEIVER 5-HT6.
ES2228267B1 (en) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. COMBINATION OF ACTIVE SUBSTANCES CONTAINING AT LEAST ONE COMPOUND WITH AFFINITY FOR THE NEUROPEPTIDE RECEIVER AND (NPY) AND AT LEAST ONE COMPOUND WITH AFFINITY FOR THE RECEIVER 5-HT6.
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc Human g-protein chemokine receptor (ccr5) hdgnr10
EP1945658A4 (en) * 2005-09-22 2012-05-30 Yeda Res & Dev Diastereomeric peptides for modulating t cell immunity
DK2121919T3 (en) 2007-03-22 2012-05-21 Heptares Therapeutics Ltd MUTANTE G PROTEIN-CONNECTED RECEPTORS AND METHODS FOR SELECTION THEREOF
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
CA2884220A1 (en) * 2012-10-08 2014-04-17 F. Hoffmann-La Roche Ag Cell penetrating peptides which bind irf5

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005695A1 (en) * 1992-09-10 1994-03-17 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
WO1994019002A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Regulator regions of g proteins
WO1994024162A1 (en) * 1993-04-21 1994-10-27 Vetigen NUCLEOTIDE SEQUENCES CODING FOR THE BOVINE β3-ADRENERGIC RECEPTOR, AND APPLICATIONS THEREOF
WO1996022306A1 (en) * 1995-01-16 1996-07-25 Northern Sydney Area Health Service Novel peptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005695A1 (en) * 1992-09-10 1994-03-17 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
WO1994019002A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Regulator regions of g proteins
WO1994024162A1 (en) * 1993-04-21 1994-10-27 Vetigen NUCLEOTIDE SEQUENCES CODING FOR THE BOVINE β3-ADRENERGIC RECEPTOR, AND APPLICATIONS THEREOF
WO1996022306A1 (en) * 1995-01-16 1996-07-25 Northern Sydney Area Health Service Novel peptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G.Y.K. NG ET AL.: "Dopamine D2 Receptor Dimers and Receptor-Blocking Peptides", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 227, no. 1, 3 October 1996 (1996-10-03), ORLANDO, FL US, pages 200 - 204, XP002038452 *
HEBERT T E ET AL: "A PEPTIDE DERIVED FROM A BETA2-ADRENERGIC RECEPTOR TRANSMEMBRANE DOMAIN INHIBITS BOTH RECEPTOR DIMERIZATION AND ACTIVATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 27, 5 July 1996 (1996-07-05), pages 16384 - 16392, XP002045155 *
M. FAINZILBER ET AL.: "New Sodium Channel-Blocking Conotoxins Also Affect Calcium Currents in Lymnaea Neurons", BIOCHEMISTRY, vol. 34, no. 16, 25 April 1995 (1995-04-25), EASTON, PA US, pages 5364 - 5371, XP002061899 *
WAGNER T ET AL: "DIFFERENTIAL REGULATION OF G-PROTEIN ALPHA-SUBUNIT GTPASE ACTIVITY BY PEPTIDES DERIVED FROM THE THIRD CYTOPLASMIC LOOP OF THE ALPHA2-ADRENERGIC RECEPTOR", FEBS LETTERS, vol. 365, no. 1, 1995, pages 13 - 17, XP002045148 *

Also Published As

Publication number Publication date
WO1997035881A2 (en) 1997-10-02
CA2250567A1 (en) 1997-10-02
EP0906339A2 (en) 1999-04-07
AU2020497A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
WO1997035881A3 (en) Receptor and transporter antagonists
ES2147558T3 (en) NEW POLYPEPTIDES TO PROMOTE CELL FIXATION.
EP1803733A3 (en) Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
BRPI9814499B1 (en) Synthetic opioid amide peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical composition
NO964650D0 (en) LAG-3 protein-soluble polypeptide fractions, method of preparation, therapeutic preparation and anti-idiotype antibody
NZ315809A (en) Opiate tetrapeptides with a tyr (or 2',6'-dimethyl tyr) at one terminus and an optionally substituted amino at the other terminus
WO1998055508A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
CA2249180A1 (en) Methods for recombinant microbial production of bpi-fusion proteins and bpi-derived peptides
EP0875567A3 (en) Mycbinding Zinc-finger proteins, preparation and use thereof
WO2004005317A3 (en) Thrombin peptide derivative dimers
EP0737690A3 (en) Antihypertensive agent from casein and method for preparing same
GB9311454D0 (en) Pharmaceutical compositions
WO2005058953A3 (en) Ogh fusion polypeptides and therapeutic uses thereof
WO1999048908A3 (en) NGF TrkA RECEPTOR IMMUNOREACTIVE POLYPEPTIDE AND USES
EP0688319A4 (en) 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
WO2002055669A3 (en) Regulation of target protein activity through modified proteins
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
AU2865801A (en) Therapeutic peptides
WO1999021994A3 (en) Human vesicle membrane protein-like proteins
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
WO1992016623A3 (en) Receptors for bombesin-like peptides
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
CA2112701A1 (en) Proteins s polypeptides and uses thereof
EP2143730A3 (en) Modified peptides and their use for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2250567

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2250567

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1997908101

Country of ref document: EP

NENP Non-entry into the national phase

Ref document number: 97533893

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997908101

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997908101

Country of ref document: EP